| Literature DB >> 36146778 |
Marco Zuin1, Giacomo Mugnai1, Maurizio Anselmi2, Stefano Bonapace3, Paolo Bozzini2, Fabio Chirillo4, Ada Cutolo5, Giuseppe Grassi6, Daniela Mancuso7, Samuele Meneghin7, Giulio Molon3, Antonio Mugnolo8, Ivan Pantano9, Angela Polo4, Paola Purita10, Loris Roncon11, Salvatore Saccà10, Daniele Scarpa6, Domenico Tavella12, Sakis Themistoclakis5, Giovanni Turiano13, Roberto Valle9, Maddalena Widmann12, Edlira Zakja13, Alberto Zamboni8, Gianluca Rigatelli14, Claudio Bilato1.
Abstract
Background: During the COVID-19 pandemic, the risk of SARS-CoV-2 infection, the public health measures of social distancing, the freedom limitations, quarantine, and the enforced homeworking under the lockdown period, as well as medical causes including COVID-19 infection per se, may have caused major emotional distress, especially in the most vulnerable patients. We aimed to evaluate the variations in the number of admissions due to Takotsubo syndrome (TTS) during the COVID-19 pandemic in the Veneto region.Entities:
Keywords: COVID-19; Takotsubo; epidemiology
Mesh:
Year: 2022 PMID: 36146778 PMCID: PMC9506046 DOI: 10.3390/v14091971
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.818
Figure 1(A) Trends in Takotsubo syndrome hospital admission in Veneto region. Periods: 2018/1: between 15 March and 30 April 2018; 2018/2: between 15 November and 30 December 2018; 2019/1: between 15 March and 30 April 2019; 2019/2: between 15 November and 30 December 2019; 2020/1: between 15 March and 30 April 2020; 2020/2: between 15 November and 30 December 2020. (B) Crude incidence of Takotsubo syndrome over the years in Veneto region (per 100,000 inhabitants). * p < 0.05 compared to 2020; p for difference between 2018 vs 2019 = 0.621.
Figure 2Map of the Veneto region showing the areas with the highest incidence of Takotsubo syndrome during the first and second pandemic waves.
Trends in Takotsubo (TTS) event rates also stratified by gender between 2018 and 2020. CI: confidence interval.
| Annual Percentage Change (95% CI) |
| |
|---|---|---|
| Overall | +1.75 (1.72–1.78) | 0.006 |
| Men | +1.3 (1.1–1.4) | 0.02 |
| Women | +2.2% (2.0–2.4) | 0.001 |
Baseline characteristics, clinical presentation, and outcomes.
| Variables | 2020 Cohort | Historical Cohort (2018–2019) |
|
|---|---|---|---|
| Age (years) | 73.5 ± 11.7 | 69.2 ± 11.1 | 0.941 |
| Age ≥65 years (%) | 27 (84.4) | 39 (70.9) | 0.163 |
| Female, n (%) | 30 (93.8) | 48 (87.3) | 0.332 |
| Arterial hypertension, n (%) | 26 (81.2) | 27 (49.1) | 0.042 |
| Diabetes mellitus, n (%) | 1 (3.1) | 8 (14.5) | 0.032 |
| Dyslipidemia, n (%) | 14 (43.8) | 28 (50.9) | 0.527 |
|
| |||
| None | 11 (34.4) | 15 (27.3) | 0.488 |
| Emotional | 14 (43.8) | 19 (34.5) | 0.396 |
| Physical | 6 (18.6) | 17 (30.9) | 0.217 |
| Emotional and physical | 1 (3.1) | 4 (7.3) | 0.422 |
| Positive COVID-19 (at the admission for TTS), n (%) | 3 (9.4) | - | - |
|
| |||
| None, n (%) | 1 (3.1) | 3 (5.5) | 0.606 |
| Chest pain, n (%) | 24 (75.0) | 38 (69.1) | 0.553 |
| Dyspnea, n (%) | 5 (15.6) | 9 (16.4) | 0.925 |
| Syncope, n (%) | 3 (9.4) | 5 (9.1) | 0.967 |
|
| |||
| Normal, n (%) | 9 (29.0) | 10 (18.2) | 0.247 |
| ST-segment elevation, n (%) | 10 (32.3) | 20 (36.4) | 0.705 |
| ST-segment depression, n (%) | 2 (6.5) | 4 (7.3) | 0.882 |
| Negative T waves, n (%) | 16 (32.3) | 21 (38.2) | 0.586 |
| Mean length of stay (days) | 5.4 ± 2.3 | 8.5 ± 2.8 | 0.021 |
|
| |||
| Significant coronary artery disease | 2 (6.2) | 6 (10.9) | 0.464 |
| Troponin T, ng/L | 325 (51–1278) * | 76 (29–586) ** | 0.003 |
| Troponin I, ng/L | 675 (126–3675) § | 345 (38–3276) §§ | 0.002 |
| LVEF (%) | 49.6 ± 10.3 | 49.4 ± 8.7 | 0.918 |
|
| |||
| None, n (%) | 29 (90.3) | 47 (92.2) | 0.766 |
| AF, n (%) | 2 (6.5) | 2 (3.9) | 0.586 |
| NSVT, n (%) | 1 (3.2) | 0 | 0.216 |
| SVT, n (%) | 2 (3.9) | 0 | 0.166 |
| VF, n (%) | 0 | 0 | - |
| 2nd or 3rd AV blocks, n (%) | 0 | 0 | - |
|
| |||
| Normal, n (%) | 16/21 (76.1) | 43/46 (93.4) | 0.041 |
| Edema, n (%) | 3 (14.2) | 2 (4.3) | 0.152 |
| LGE, n (%) | 2 (9.5) | 1 (2.1) | 0.172 |
|
| |||
| Re-hospitalization, n (%) | 1 (3.1) | 5 (9.1) | 0.282 |
| In-hospital mortality, n (%) | 0 | 2 (3.6) | 0.296 |
TTS: Takotsubo syndrome; LVEF: left ventricular ejection fraction: AF: atrial fibrillation; NSVT: non-sustained ventricular tachycardia; SVT: sustained ventricular tachycardia; VF: ventricular fibrillation; LGE: late gadolinium enhancement. * Data available for 12 patients; ** data available for 24 patients. § data available for 10 patients; §§ data available for 26 patients.